Zenith

Mild to moderate community-acquired pneumonia caused by Mycoplasma pneumoniae, Chlamydophila psittaci (ornithosis) or Chlamydophila pneumoniae (TWAR). Acute exacerbation of chronic bronchitis. Acute bacterial sinusitis. Tonsillitis, pharyngitis, acute otitis media, & skin & soft tissue infections (eg, furunculosis, pyoderma, impetigo & erysipelas) in patients w/ hypersensitivity to β-lactam antibiotics or when such treatment is not suitable. Uncomplicated genital infections caused by Chlamydia trachomatis or Neisseria gonorrhoeae.

Adult Uncomplicated genital infections due to Chlamydia trachomatis or sensitive Neisseria gonorrhoeae 1,000 mg as single dose. Other indications 500 mg daily for 3 consecutive days. Alternatively, 500 mg on the 1st day then 250 mg on the 2nd-5th day. Childn >45 kg Normal adult dose.

May be taken with or without food: Swallow whole, do not chew/crush.

Hypersensitivity to azithromycin monohydrate, erythromycin, & to any macrolide or ketolide antibiotics.

Discontinue if an allergic reaction occurs. Fulminant hepatitis potentially leading to life-threatening liver failure in patients w/ preexisting hepatic disease or taking other hepatotoxic medicinal products. Perform LFT in case of signs & symptoms of liver dysfunction eg, rapid developing asthenia associated w/ jaundice, dark urine, bleeding tendency or hepatic encephalopathy. Discontinue immediately if signs & symptoms of hepatitis occur. Infantile hypertrophic pyloric stenosis in neonates (treatment up to 42 days of life). Pseudomembranous colitis. Observe for signs of superinfection w/ non-susceptible organisms, including fungi. Cross-resistance w/ erythromycin-resistant gm +ve strains & methicillin-resistant staphylococci strains. Not intended for severe infections where fast high blood conc of antibiotic have to be achieved. Clostridium difficile-associated diarrhoea. Patients w/ ongoing proarrhythmic conditions (especially women & elderly) eg, w/ congenital or documented QT prolongation; current treatment w/ other active substances that prolong QT interval eg, antiarrhythmics class IA (quinidine & procainamide) & class III (dofetilide, amiodarone, & sotalol), cisapride, terfenadine, antipsychotics (eg, pimozide), antidepressants (eg, citalopram), & fluoroquinolones (eg, moxifloxacin & levofloxacin); electrolyte disturbance, particularly hypokalaemia & hypomagnesaemia; clinically relevant bradycardia, cardiac arrhythmia or severe cardiac insufficiency. Exacerbations of the symptoms of myasthenia gravis & new onset of myasthenia syndrome. Long-term use. Neurological & psychiatric disorders. Should not be co-administered w/ ergot derivatives. Visual impairment & blurred vision may have an effect on ability to drive or operate machinery. Significant hepatic disease & severe renal impairment (GFR <10 mL/min). Pregnancy & lactation. Childn <45 kg.

Diarrhoea. Headache; vomiting, abdominal pain, nausea; decreased lymphocyte count & blood bicarbonate; increased eosinophil count, basophils, monocytes, & neutrophils.

Reduced peak serum conc w/ antacids. Increased serum levels of P-gp substrates (eg, digoxin & colchicine). Ergotism w/ ergot alkaloids. Increased conc of phosphorylated zidovudine. Rhabdomyolysis w/ statins. Potentiated anticoagulation w/ coumarin-type oral anticoagulants eg, warfarin. Elevated C_max & AUC_0-5 of cyclosporine. Increased conc w/ nelfinavir. Neutropenia may occur w/ rifabutin. Co-resistance w/ other macrolides. Medicinal products known to prolong QT interval.

Macrolides

J01FA10 - azithromycin ; Belongs to the class of macrolides. Used in the systemic treatment of infections.

Rx